Instituto Medico Quirurgico San Rafael S.A. — Clinical Trial Site

18 Registered trials

9 Currently recruiting

Organisation

Instituto Medico Quirurgico San Rafael S.A.

Location

A Coruna, Spain

Identifier

ORG-100047470

Address

Poboado Nucleo Rural La Jubias 82, 15006, Spain

Departments

#4507: Cardiología
2809: Endocrinología
3116: Cardiología
Endocrinología
Endocrinology
Endocrinology and Matabolism
Endrocrinology
Instituto MQ San Rafael - Servicio de cardiología
NA
Servicio de Endocrinologia
Servicio de Endocrinología y Nutrición
Soto Gonzalez

Clinical trials at this site (18)

Search interface

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting

2025-523659-73-00 Obesity 5 2026-05-11
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
A Phase 3 Trial of K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg Recruiting

2025-523739-20-00 Hypercholesterolemia 5 2026-05-14
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
AMAZE 5: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose… Recruiting

2024-520444-42-00 Overweight or obesity, and knee osteoarthritis 5 2026-04-15
AMAZE 6: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose… Recruiting

2024-520445-23-00 Overweight or obesity, and knee osteoarthritis 5 2026-04-15
Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting

2024-516356-18-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-02-17
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-… Recruiting

2025-522703-14-00 "Moderate to severe obstructive sleep apnea (OSA) in ad 5 2026-02-17
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN ) Recruiting

2025-522631-34-00 Osteoarthritis 5 2026-01-14
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening);… Ended

2024-519000-27-00 Hypertension 5 2025-07-17
A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended

2024-519561-22-00 Obesity 4 2025-07-07
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended

2023-504922-20-00 Hypercholesterolemia 5 2024-08-23
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P… Ended

2024-511126-31-00 Non-obstructive Coronary Artery Disease 5 2022-08-16
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
MK-0616 versus Comparators Study in Adults with Hypercholesterolemia Ended

2023-504920-25-00 Hypercholesterolemia 5 2024-08-23